Nick Traggis

In a conversation with Rinnovabili, I shared Modern Meadow’s vision and how we’ve bioengineered INNOVERA™, a leather alternative that matches and even surpasses traditional materials in strength, toughness and durability. When it comes to the adoption of new materials, scalability is essential, and we’ve designed our technologies with this in mind so that manufacturers don’t have to make significant capital investments. Additionally, our technologies are aligned with the movement toward a circular economy, enabling waste reduction, lower emissions and products designed for longevity. See more below and read the full story: https://lnkd.in/egm6Neux

25

1 Comment

Founder & CEO of Ourobionics John Zandbergen talks about scaling human tissue & biosenor production since forming in 2021. Imagine hundreds or thousands of 3D bio-electrojets, cell-electrospinners, & bio-electrosprays creating complex human skin, heart or lung tissue merged with self-healing bioelectronics & disease biomarker biosenors at a scalable level. This could lead to a future where drugs no longer fail at the clinic after animal testing! By replacing it with scalable human tissue production with tens or hundreds of biomarker readouts when merged with bioelectronic biosenors. Or a future of developing cellular or genetic human tissue therapeutics to treat and reverse diseases. A single bio-electrojet, cell-electrospinner, or bio-electrospray is already 30X faster than older existing extrusion technology without any cell damage, deformation, or death. The bio-electric deep technology has the published ability to create complex human tissue at high speeds in porous scaffolding with 96% cell viability & cell pluripotency/differentiation potential remaining intact. The bio-electric field technologies are also published to fully encapsulate at cellular or genetic level for further applications in tissue therapeutics for regenerative medicine. #biotech #VC #venturecapital #regenerativedicine #animaltesting #deeptech #innovation #science #engineering #biotechnology #stemcells #bioelectricfield #bipelectrojets

30

1 Comment

🚀 Exciting developments in the fight against cancer! Dr. Daniel Chen, M.D. Ph.D., my friend and Genesis BioCapital colleague renowned for co-authoring the Cancer Immunity Cycle and leading the development of TECENTRIQ® at Genentech, has launched Synthetic Design Lab! Their groundbreaking SYNTHBODY™ platform aims to enhance targeted payload delivery by over 10 times compared to current ADCs, potentially transforming cancer treatment. ​Backed by $20 million in seed funding from investors including Playground Global and Godfrey Capital, Synthetic Design Lab plans to initiate clinical trials next year. This venture exemplifies the convergence of synthetic biology, AI, and immuno-oncology to address critical challenges in cancer therapy.​ Very excited for you and your team Dan! Thank you for all you do for patients and their families in need of breakthrough technologies! #CancerResearch #Immunotherapy #SyntheticBiology #BiotechInnovation #ADCTherapy #ADCs #Oncology #SYNTHBODY #DanielChen #Cancer #SyntheticDesignLab #HOPE

14

📢 Hemostemix Secures $330,000 Insider Lead Order for Private Placement Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a lead order of $330,000 for its non-brokered private placement of up to $700,000. Each Unit, priced at $0.11, consists of one common share and one warrant exercisable at $0.15 for two years from the closing date. Proceeds will support general working capital and continued marketing and sales of ACP-01, Hemostemix’s proprietary autologous stem cell therapy. Read the full release here 👉 https://lnkd.in/gMk7-3rX #Hemostemix #HMTXF #2VF0 #Biotech #StemCellTherapy #InvestorRelations #PrivatePlacement #RegenerativeMedicine #LifeSciences

9

Excited to announce a major step forward for Lygos and the broader #bioeconomy. We’ve entered into a new collaboration with BioMADE, a Department of Defense –sponsored institute, to transition operations of our state-of-the-art pilot facility in Hayward. This partnership builds on an already strong relationship and creates a true win–win: ✅ BioMADE gains access to a best-in-class biomanufacturing asset to support innovation across the U.S. ✅ Lygos sharpens its focus on commercializing performance solutions — while retaining access to pilot-scale capabilities in Hayward. We’re proud to see this facility continue to play a national role and to contribute to strengthening domestic biomanufacturing. Press release: https://lnkd.in/gzzXdEjw #performance #bioeconomy #biomanufacturing #sustainability #partnerships #DoD #innovation #Lygos

228

18 Comments

We're starting to take a closer look at the electronics supply chain for our custom bio-hardware projects Cultivarium. We're hearing that cost, customs clearance, and shipping times are becoming more unpredictable for components, PCBs, subassemblies, etc. Want cutting-edge science and innovation? Re-industrialize the USA and re-normalize trade!

25

See this technical article : https://lnkd.in/ecjmb9kC. Most of AI is unfulfilled hype. This is the real thing: actually useful and a major disruptor.

30

5 Comments

3 Minute reading time. Time for an update, as we've not been sitting still! Since we last communicated, with most of you via Jon Flatt of Magic Bullet, we now have a lead investor, MoonshotNx and we're going through the DD process with them, to get us ready for their investor network introductions.   They are very helpful, and none of the DD process is at any immediate cost to us, which always helps, if you're a bootstrapping startup, as we are. The amount of potential sales, aka RfQ's, has increased to almost 3M dollars, but as you can understand, because we are still lacking our own collection facilities, as distributors we rely on product and quality from competitors. With past experiences under our belt, we stopped such distribution altogether, except for a very few Customers, who insist we scour the market for them. Even so, we have signed some new Customers too, the most important one being BioMarin Pharmaceuticals, operating out of San Rafael, CA with some 2500 employees globally. Thanks to our full transparency it was actually relatively simple for us to get this account, once again showing how difficult it is to have reliable and consistent access to good research material. More and more researchers are reconfirming to us that individualized samples and personalized medicine are the way of the future. The lack of one-cure-fits-all unicorn drugs proofs that time and again, just as the endless side-effects and the "results-may-vary" warning are just indicators to the fact that we are all different. And therefore, personalization of medicine will prove to be more effective! Not to mention way more efficient! One more thing, we now have received already 6 M&A offers, but as you can understand when those companies think we are too early as startups, we the founders, having so far invested over 1.25M altogether, we too think it is too early; but it doesn't mean that 6 M&A's and ~3M in potential sales are not giving us any leverage. Au contraire, we just want to get this off the ground as the new direction for all research, so that it ultimately will lead to cures and who knows, maybe even preventative measures, for all mankind. Something the research industry has been chasing very intensely now for 80+ years. But still no cures, just indefinite treatments! Thank you for reading. We look forward to hearing from you soon. Sincerely, Jan Breukers First Choice Bio Inc. CEO and Logistics T: +1-707-333-0902 E: jan@firstchoicebio.com https://lnkd.in/gy7sqdKB https://quickcells.com For Investors: https://quickcells.net CUSTOMERS FIRST! To schedule an appointment please follow the link below: https://lnkd.in/gpdFGWHm

3

BIG news from BUILT! BUILT Biotechnologies, Inc. is onboarding 50+ new customers who rely on high-fidelity, large-scale DNA — and we’re growing the team to support them. Please join me in welcoming industry veterans Steven Riedmuller and Amanda Skeen! This expansion lets us: • Support complex genome engineering projects with fully BUILT DNA™ • Put our expanded manufacturing capacity to work at our new lab in CvilleBioHub’s Commonwealth BioAccelerator at North Fork Research Park • Combine our zero-failure Regenerative DNA Assembly™ platform with best-in-class commercial leadership Need DNA? Consider it BUILT. Read the full press release ➜ https://lnkd.in/efhm4-pC #DNAmanufacturing #SyntheticBiology #GenomeEngineering #Biotech #Charlottesville #LifeSciences

158

12 Comments

Series: “Exploring Next-Generation Materials through Quantum Observation” — Industrial Innovations Enabled by G-Theranostics Technology — 🧪【Episode 1】Methane Conversion Catalyst & Surface Reconstruction “Watching catalysts at work in real-time” Recent research indicates that in methane conversion catalysts—particularly nickel-based—surface reconstruction during reactions strongly correlates with catalytic activity. However, conventional scanning tunneling microscopy (STM) or atomic force microscopy (AFM) have only captured these crucial structural changes as static images. How catalysts dynamically restructure their surfaces to drive reactions remains largely unknown. G-Theranostics’ patented “time-resolved STM” opens the possibility to observe this catalytic restructuring in real-time at the nanosecond scale, capturing the precise moment when a catalyst “actually works.” This could significantly advance catalyst design precision and performance improvement. ――― G-Theranostics offers a globally unique, patent-backed quantum measurement technology. However, fully unlocking its potential and addressing pressing societal needs requires close collaboration and partnerships with companies and research institutions. Through this series of posts, we aim to explore possibilities and identify how we can collaborate to shape the next generation of quantum-driven technologies. If you have an interest, ideas, or suggestions, please don't hesitate to reach out. Let's work together to innovate for the future. ――― #QuantumMeasurement #Catalysts #STM #AFM #Methane #Nanotechnology #G_Theranostics #OpenInnovation

2

Excited to share a new innovation from Ixora Scientific, developed in collaboration with Döhler: a plant-based Seasoning Modulator that enables precise tuning of spiciness, saltiness, umami, and sourness in savory applications. Formulated with natural, FEMA GRAS-approved compounds, this clean-label solution is patent pending and integrates seamlessly into soups, sauces, snacks, and ready meals. A step forward in functional flavor modulation. #FoodInnovation #SeasoningModulation #PlantBased #GRASApproved #CleanLabel #FlavorSolutions #FoodIndustry #IxoraScientific #Döhler 👉 https://lnkd.in/gjf7SjFa

26

5 Comments

This really is a game changer. MOBILion Systems, Inc. is again Revealing What Others Leave Unseen - this time for per- and polyfluoroalkyl substances – known as PFAS. Persistent little buggers that have found their way into everything, that we are only beginning to detect and study. We are super excited to be advancing characterization capabilities in this critically important food, environment and health testing application.

9

1 Comment

I am pleased to announce NEOK Bio debut funded by ABL Bio. NEOK Bio’s two lead programs, NEOK001 (ABL206; ROR1xN7-H3 ADC) and NEOK002 (ABL209; EGFRxMUC1) will be in Phase 1 next year, 2026. NEOK Bio utilized Synaffix linker and Topo1 payload (SYNtecan E). Mayank Gandi, CEO of NEOK Bio will lead the clinical development of bispecific ADC to overcome the limitations of efficacy and toxicity of conventional ADC. https://lnkd.in/g_3vqWw3

169

9 Comments

Excited to be in San Francisco for #JPMWeek. At Exodigm Biosciences, we are building to help cell therapy manufacturers and drug developers predict- early and quantitatively- when an immune response has crossed the threshold into true cytotoxic activity. By pioneering real-time, near-membrane sensing of intracellular signaling pathways in live cells, we’re creating a new biomarker intelligence layer that can fundamentally change how curative therapies are developed and manufactured. Short Explainer Video: https://lnkd.in/gXgTiwMa? This week, I’ll be focused on building meaningful relationships and connecting with investors and strategic partners, including those interested in early-stage and community-driven funding models. Looking forward to thoughtful conversations with the broader life sciences and investment community. If you’re in San Francisco, feel free to reach out. #CancerResearch #Immunotherapy #CellTherapy #Oncology #PrecisionMedicine

29

2 Comments

Efficiently scaling bio-based materials remains one of the biggest hurdles in the field. Capital intensity, complex operations, and limited design-side experience with biomanufacturing often stand between great prototypes and real-world adoption. But these challenges also open up opportunities to repurpose existing infrastructure and explore new ways of working with AI. I recently contributed a chapter—Farming Mycelium Textiles—to Designing Mycelium: Exploring the Design Potential of Fungi, edited by Assia Crawford and Jonathan Dessi-Olive. The chapter explores material farming as a design methodology, where working with living systems involves tuning biological dynamics, thermodynamic conditions, and process scalability. It introduces relational intelligence as a hybrid mode of reasoning—emerging from the interplay of organismal behavior, farmer intuition, and algorithmic control. Each contributes a distinct signal: organisms adapt to micro-environmental cues shaped by computational models, farmers respond through embodied feedback, and algorithms enable precision control while extracting high-dimensional patterns over time. Together, they offer a more ecological, creative, and profitable framework for designing with biology. Excited for the book to come out soon.

148

6 Comments

First Biological Hexavalent Chromium System Achieves Non-Detect at Scale! This milestone validates both regulatory compliance potential and the commercial readiness of our MNE platform in one of the most stringent markets in the U.S.

14

Each step in Alloy Therapeutics, Inc.’s evolution is shaped by a simple goal: to help our partners move their programs forward with the right support at the right time. For more than a decade, Spannerwerks, LLC has partnered with emerging biotechs to guide programs from preclinical strategy through clinical execution with clarity and rigor. By integrating that expertise with Alloy’s ecosystem, we’re strengthening the bridge between discovery and development. Under the continued leadership of Dara Lockert, Spannerwerks will remain focused on guiding biotechs through development and advancing Alloy’s mission of making better medicines together. #makemedicinetogether

90

1 Comment

We always prioritize placing the Videodrop at the center of labs and cores as a first-intention tool to normalize and standardize nanoparticles before advanced characterization. ✅ **Our core principle**: Repeatable, reliable, and consistent inputs always improve outputs ✅ **Direct impact**: Proper standardization upstream enhances the quality of our downstream advanced analyses This methodical approach ensures consistency and reliability in our characterization processes—essential foundations for breakthrough innovations in nanotechnology. #Nanotechnology #Laboratory #Innovation #Research #Standardization #Analytics --- This post emphasizes your systematic methodology while remaining accessible to industry professionals. Would you like me to adjust the tone or any specific elements?

7

1 Comment